At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CVM CEL-SCI Corp
Market Closed 11-22 16:00:00 EST
0.5958
-0.0087
-1.44%
盘后0.6043
+0.0085+1.43%
18:58 EST
High0.6045Low0.5800Vol308.22K
Open0.6045D1 Closing0.6045Amplitude4.05%
Mkt Cap36.64MTradable Cap35.56MTotal Shares61.49M
T/O184.56KT/O Rate0.52%Tradable Shares59.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
BRIEF-Cel-Sci Corp Says On November 13, Patricia B Prichep Has Assumed The Duties Of Chief Financial And Operations Officer
Reuters  ·  11-16
BRIEF-Cel-Sci Corp Says On November 13, Patricia B Prichep Has Assumed The Duties Of Chief Financial And Operations Officer
CEL-SCI Corp: on November 13, Patricia B Prichep Has Assumed the Duties of Chief Financial and Operations Officer
THOMSON REUTERS  ·  11-16
CEL-SCI Corp: on November 13, Patricia B Prichep Has Assumed the Duties of Chief Financial and Operations Officer
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
GlobeNewswire  ·  11-12
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand
CNW Group  ·  11-12
Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand
CEL-SCI, FDA agree on Phase 3 trial design for cancer drug
seekingalpha  ·  11-08
CEL-SCI, FDA agree on Phase 3 trial design for cancer drug
U.S. FDA and CEL-SCI Agree on Use of Pd-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
THOMSON REUTERS  ·  11-07
U.S. FDA and CEL-SCI Agree on Use of Pd-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
Business Wire  ·  11-07
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
Press Release: GERDAU S.A. - CONSOLIDATED INFORMATION
Dow Jones  ·  11-06
Press Release: GERDAU S.A. - CONSOLIDATED INFORMATION
Press Release: ITAÚ UNIBANCO - Projections
Dow Jones  ·  11-05
Press Release: ITAÚ UNIBANCO - Projections
Solana News: Canary Capital Files for New ETF, What’s Next for SOL Price?
CoinMarketCap  ·  10-31
Solana News: Canary Capital Files for New ETF, What’s Next for SOL Price?
CEL-SCI Corp Files Prospectus Relates to Possible Resale, From Time to Time, by Selling Shareholder of up to 1 Mln Shares of Common Stock
THOMSON REUTERS  ·  10-26
CEL-SCI Corp Files Prospectus Relates to Possible Resale, From Time to Time, by Selling Shareholder of up to 1 Mln Shares of Common Stock
CEL-SCI files to sell 1M shares of common stock for holders
TIPRANKS  ·  10-26
CEL-SCI files to sell 1M shares of common stock for holders
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
Business Wire  ·  10-22
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
Brazil’s Central Bank Digital Currency Unveils Drex Project
CoinMarketCap  ·  10-15
Brazil’s Central Bank Digital Currency Unveils Drex Project
Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs
CNW Group  ·  10-12
Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs
Embark on the Conflux Tech Odyssey: Mapping Out the Next 3–5 Years!
CoinMarketCap  ·  10-01
Embark on the Conflux Tech Odyssey: Mapping Out the Next 3–5 Years!
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
Business Wire  ·  10-01
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
LATAM Crypto Roundup: Nexo Joins Colombia Fintech Association, Worldcoin Expands to Guatemala, and More
BE[IN]CRYPTO  ·  09-29
LATAM Crypto Roundup: Nexo Joins Colombia Fintech Association, Worldcoin Expands to Guatemala, and More
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
Business Wire  ·  09-16
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
Cryptocurrency Market Overview - August 2024
CoinMarketCap  ·  09-13
Cryptocurrency Market Overview - August 2024
No data available

Introduction

Company Name.
CEL-SCI Corp
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Issue price:
--